NASDAQ:BCYC

Bicycle Therapeutics Stock Forecast, Price & News

$35.31
+0.40 (+1.15 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.90
$36.99
50-Day Range
$28.75
$35.31
52-Week Range
$15.25
$36.99
Volume384,500 shs
Average Volume144,671 shs
Market Capitalization$850.19 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.35
30 days | 90 days | 365 days | Advanced Chart
Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Bicycle Therapeutics logo

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

838th out of 2,214 stocks

Pharmaceutical Preparations Industry

399th out of 867 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bicycle Therapeutics?

Wall Street analysts have given Bicycle Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bicycle Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Bicycle Therapeutics
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) posted its earnings results on Thursday, May, 6th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.05. The firm earned $1.81 million during the quarter, compared to analysts' expectations of $1.95 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 53.45% and a negative net margin of 504.81%.
View Bicycle Therapeutics' earnings history
.

How has Bicycle Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BCYC shares have increased by 99.5% and is now trading at $35.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BCYC?

6 analysts have issued 1 year target prices for Bicycle Therapeutics' shares. Their forecasts range from $36.00 to $58.00. On average, they anticipate Bicycle Therapeutics' share price to reach $46.00 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Exec. Director (Age 52, Pay $1.16M)
  • Mr. Lee H. Kalowski, Pres & CFO (Age 40, Pay $756.13k)
  • Sir Gregory Paul Winter, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 70, Pay $40k)
  • Dr. Michael Skynner Ph.D., B.sc. Ph.d., Chief Operating Officer (Age 51, Pay $769.01k)
  • Dr. Nigel Crockett, Chief Bus. Officer (Age 56, Pay $568.12k) (LinkedIn Profile)
  • Dr. Dominic Smethurst M.A., M.D., Chief Medical Officer (Age 47, Pay $431.7k)
  • Dr. Christian Heinis, Scientific Founder
  • Dr. Nicholas Keen, Chief Scientific Officer (Age 52) (LinkedIn Profile)
  • Mr. David E. Borah CFA, VP of Capital Markets & Investor Relations
  • Mr. Zafar Qadir, Gen. Counsel

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $35.31.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $850.19 million and generates $10.39 million in revenue each year. The company earns $-51,010,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 87 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

Where are Bicycle Therapeutics' headquarters?

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.


This page was last updated on 7/26/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.